Altay Therapeutics, Inc.
San Carlos, CA
- UEI
- DXGQLLP9NQ59
- CAGE
- 8CFV4
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 733 Industrial Rd, San Carlos, CA 94070, USA
- Website
- altaytherapeutics.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| The development of a STAT3 inhibitor for lung scleroderma - abstract/summary systemic sclerosis (SSC) is an autoimmune… | National Heart Lung and Blood Institute | $299,999 | |
| Sbir phase i: targeting the root cause of ewing?s sarcoma -the broader impact of this small business innovation research… | National Science Foundation | $275,000 | |
| Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer . - abstract/summary epithelial ovarian cancer (OC)… | National Cancer Institute | $799,738 | |
| Development of a direct DUX4 inhibitor for facioscapulohumeral muscular dystrophy (fshd) - abstract/summary… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $598,429 | |
| The development of a transcriptional inhibitor for lung fibrosis. - abstract/summary idiopathic pulmonary fibrosis (IPF)… | National Heart Lung and Blood Institute | $598,136 |
About Altay Therapeutics, Inc.
Altay Therapeutics, Inc. is a biotechnology company focused on developing novel small molecule therapies targeting transcription factors for treating chronic illnesses and cancers. The company has received multiple federal grant awards to support its research and development efforts in areas such as lung fibrosis, ovarian cancer, muscular dystrophy, and Ewing's sarcoma. Altay Therapeutics utilizes a proprietary platform technology that enables the identification of small molecule binding pockets within intrinsically disordered domains of previously undruggable transcription factors, allowing for the development of potent and specific inhibitors.
Through its federal grant awards, Altay Therapeutics has pursued several research projects aimed at developing innovative treatments. These include: a STAT3 inhibitor for lung fibrosis associated with systemic sclerosis, funded by the National Heart, Lung, and Blood Institute; a STAT3 inhibitor for overcoming chemoresistant ovarian cancer, supported by the National Cancer Institute; a direct inhibitor of the DUX4 transcription factor for facioscapulohumeral muscular dystrophy (FSHD), funded by the National Center for Advancing Translational Sciences; and a transcriptional inhibitor for idiopathic pulmonary fibrosis, also funded by the National Heart, Lung, and Blood Institute. Additionally, the company received funding from the National Science Foundation to develop small molecule therapies targeting the EWS-FLI1 fusion protein in Ewing's sarcoma. These projects typically involve in vitro and in vivo studies to characterize lead compounds, evaluate their efficacy and safety, and advance promising candidates towards further development and potential commercialization.
Quick answers
What is Altay Therapeutics, Inc.'s UEI?
Altay Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is DXGQLLP9NQ59.
What is Altay Therapeutics, Inc.'s CAGE code?
Altay Therapeutics, Inc.'s CAGE code is 8CFV4.
Where is Altay Therapeutics, Inc. located?
Altay Therapeutics, Inc.'s physical address in SAM.gov is 733 Industrial Rd, San Carlos, CA 94070, USA.
Is Altay Therapeutics, Inc. registered in SAM.gov?
Yes. Altay Therapeutics, Inc.'s SAM.gov registration is active through December 23, 2026.
What is Altay Therapeutics, Inc.'s most recent federal award?
Altay Therapeutics, Inc.'s most recent federal grant award is The development of a STAT3 inhibitor for lung scleroderma - abstract/summary systemic sclerosis (SSC) is an autoimmune… (R43HL172594), from National Heart Lung and Blood Institute, on May 15, 2024.
On GovTribe
See Altay Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors